RGEN

Repligen Corp. 10-Q Summary: Quarter Ended June 30, 1996

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 1996 (Fiscal Q1 1997). Repligen Corporation, a biotechnology firm, is in a post-restructuring phase following a major downsizing in Fiscal 1996. The company has consolidated operations, terminated several research programs, and closed its Cambridge facility, relocating to Needham, Massachusetts. As of June 30, 1996, the company employed approximately 15 people. The strategy focuses on internal research for inflammation and immunosuppression therapies while relying on third parties for manufacturing and clinical development.

Key Financial Metrics

Revenue Breakdown (Q1 1997): Research & Development ($257,085), Product ($226,099), Investment Income ($32,203), and Other ($324,868).

Expense Breakdown (Q1 1997): Research & Development ($323,763), Selling, General & Administrative ($833,857), Cost of Goods Sold ($151,649).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues dropped 70% to $840,000 from $2.8 million. This was driven by a 88% drop in R&D revenue (due to the termination of the Lilly collaboration and Partnership agreement) and a 42% drop in product revenue (timing of Protein A shipments).
• Expense Reduction: Total expenses fell 76% to $1.3 million from $5.5 million. R&D expenses decreased 91% and SG&A expenses decreased 38% due to workforce reductions and facility consolidation.
• Loss Narrowing: Net loss improved significantly to $469,000 from $2.6 million, reflecting the drastic cost-cutting measures.
• Liquidity Impact: Cash and equivalents decreased by approximately $3.8 million during the quarter. This burn was primarily due to net operating losses, the reduction of accounts payable, and significant payments ($2.47 million) related to accrued restructuring obligations (lease settlements and severance).
• One-Time Items: "Other" revenue increased due to a one-time sale of non-investment securities for approximately $300,000.

Outlook, Risks, and Management Commentary

Outlook: Management believes current cash reserves ($3.3 million including marketable securities) are sufficient to sustain operations at current levels for at least the next 24 months. Significant expansion of research or clinical efforts is contingent upon future financing or new partnerships with pharmaceutical companies.

Risks and Contingencies:

• Restructuring Obligations: A remaining balance of $125,000 in accrued severance is expected to be paid within the next year. Additionally, $250,000 of cash is restricted in an escrow account for facility refurbishment.
• Partnership Terminations: The company terminated agreements with Eli Lilly (Sept 1995) and the Partnership (April 1996), resulting in the loss of significant recurring revenue streams.
• Forward-Looking Statements: Actual results may differ materially from historical results due to risks inherent in biotechnology development and the need for external capital.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the 24-month cash runway estimate given the high burn rate ($3.6M operating cash outflow in one quarter).
• Revenue Sustainability: Assess the viability of the new R&D revenue streams (Pfizer, Glaxo Wellcome) to replace the lost Lilly and Partnership funding.
• Restructuring Completion: Confirm that the $125,000 remaining accrued severance and the $250,000 restricted cash escrow are the only remaining liabilities from the Fiscal 1996 restructuring.
• Product Mix: Investigate the stability of Protein A product sales, as revenue timing was cited as a primary driver for the quarter's product revenue decline.